Our findings may offer novel therapeutic insights into targeting ASM-ceramide-MR redox signaling or TXNIP to suppress the activation of endothelial NLRP3 inflammasomes, thereby preventing and treating vasculopathy associated with hypercholesterolemia. Here, NLRP3 is linked to familial hypercholesterolemia.